HCA Healthcare, Inc. HCA

HCA Healthcare, Inc. es una empresa holding. La Compañía, a través de sus subsidiarias, posee y opera hospitales y entidades de atención médica relacionadas. Posee y opera aproximadamente 182 hospitales, compuestos por 175 hospitales generales de atención aguda; cinco hospitales psiquiátricos; y dos hospitales de rehabilitación. La Compañía también opera alrededor de 125 centros de cirugía independientes y más de 21 centros de endoscopia independientes. La Compañía opera en dos grupos organizados geográficamente: el Grupo Nacional y el Grupo Americano. El Grupo Nacional incluye 96 hospitales ubicados en Alaska, California, Florida, Georgia, Idaho, Indiana, norte de Kentucky, Nevada, Nuevo Hampshire, Carolina del Norte, Carolina del Sur, Utah y Virginia. El Grupo Americano incluye aproximadamente 79 hospitales ubicados en Colorado, Kansas, sur de Kentucky, Luisiana, Missouri, Tennessee y Texas. La Compañía también opera siete hospitales en Inglaterra. Sus instalaciones están ubicadas en más de 20 estados y en Inglaterra.

Con 2 acciones de HCA (USD 872,99) habrías recibido USD 6,12 en dividendos en los últimos 12 meses.

• Zacks Investment Research 30 sept

  Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

  Tenet Healthcare (THC) is accelerating share buybacks and raising 2026 free cash flow guidance to $1.825-$2.055 billion, supported by 27.1% year-over-year growth in operating cash flow to $2.2 billion. The company has $2.1 billion remaining in buyback authorization while continuing to invest in growth initiatives and managing debt obligations.

  

• Zacks Investment Research 22 sept

  Can Pediatrix Sustain Growth Despite Lower Patient Volumes?

  Pediatrix Medical Group (MD) reported 4% YoY revenue growth to $487.8 million in Q2 2026, driven by improved reimbursement and higher patient acuity, offsetting a 2.1% decline in patient volumes. The company reaffirmed its 2026 adjusted EBITDA guidance of $280-$300 million, though volume trends and easing collection benefits remain key risks.

  

• Zacks Investment Research 4 sept

  Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?

  Charles River Laboratories (CRL) shares have gained 10.5% since its Q2 2026 earnings report, outperforming the S&P 500. The company beat earnings estimates with non-GAAP EPS of $3.02 and raised its 2026 guidance, though revenues declined 2.7% year-over-year. However, estimates have been trending downward since the earnings release, and the stock carries weak VGM scores despite maintaining a Zacks Rank #2 (Buy) rating.

  

• Zacks Investment Research 28 ago

  Can Operational Resiliency Protect HCA's Long-Term Profitability?

  HCA Healthcare is leveraging its multi-year resiliency program focused on digital transformation and shared services to control unit costs and maintain profitability despite facing a $1.0-$1.2 billion headwind from health insurance exchange disenrollment in 2026. The company achieved flat year-over-year cost per admission in Q2 and targets 4-6% long-term adjusted EBITDA growth. Peers Tenet Healthcare and Universal Health Services are similarly pursuing operational efficiency initiatives.

  

• GlobeNewswire Inc. 4 ago

  HCA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating HCA Healthcare, Inc. on Behalf of HCA Stockholders and Encourages Investors to Contact the Firm

  Law firm Bragar Eagel & Squire is investigating HCA Healthcare for potential federal securities law violations following the company's July 14, 2026 announcement of sharply lowered full-year profit guidance due to unfavorable payer mix changes impacting revenue by approximately $400 million. HCA's stock fell 6.95% ($27.14 per share) to $363.60 on the news. The firm is seeking stockholders who suffered losses to participate in the action.